PRA Health Sciences
Appearance
Company type | Subsidiary |
---|---|
Nasdaq: PRAH | |
Industry | Pharmaceuticals & Biotechnology |
Founded | 1976 Charlottesville, Virginia, U.S. |
Headquarters | , U.S. |
Area served | Worldwide |
Key people | Colin Shannon (President and CEO) |
Revenue | |
Number of employees | 17,000+[1] |
Parent | ICON plc |
Website | prahs |
PRA Health Sciences was a contract research organization (CRO) with headquarters in Raleigh, North Carolina. It was established in 1976 and acquired by ICON in 2021.
Background
[edit]PRA was founded as the Anti-Inflammatory Drug Study Group in 1976, renamed PRA in 1982, as it expanded into other therapeutic areas besides inflammation.[2] In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019.[3] In August 2017, the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.[4] PRA's 2018 revenue was US$2.87 billion.[5] PRA was acquired by ICON PLC on 1 July 2021.[6]
References
[edit]- ^ a b c "PRA 10-K For the fiscal year ended December 31, 2017". PRA Health Sciences via SEC Edgar. 2018-02-02. See SEC Edgar index page for PRA for updates
- ^ "PRA Health Sciences becomes latest big CRO to launch IPO". CenterWatch News Online. 13 November 2014.
- ^ "PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase". Globenewswire. September 3, 2019.
- ^ Liu, Angus (August 8, 2017). "PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2". FierceBiotech.
- ^ "Investors | ICON PLC".
- ^ "ICON acquisition creates world-leading healthcare intelligence and clinical research organisation" (Press release). 1 July 2021.